drugset / Trial / NCT00452387
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine if the combination of mitoxantrone, prednisone and sorafenib will improve the time to progression of advanced stage metastatic hormone-refractory prostate cancer.
Timeline
- Start
- 2007-05
- Primary completion
- 2008-07
- Completion
- 2009-01
Outcome
Outcome not reported
Stopped: “Early stopping rule”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mitoxantrone | Small molecule | 9 mg/m2 | — |
| Subject | Mitoxantrone | Small molecule | 12 mg/m2 | — |
| Subject | Prednisone | Other / unclassified | 5 mg | — |
| Subject | Sorafenib | Small molecule | 400 mg | — |